SCHEMBL4337813

SCHEMBL4337813

Fc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.68
ALDH1A1 P00352 1/20 0.68
RECQL P46063 1/20 0.68
KMT2A Q03164 1/20 0.68
LMNA P02545 1/20 0.67
CYP1A2 P05177 1/20 0.67
PTGS1 P23219 1/20 0.67
SLC6A2 P23975 1/20 0.67
CYP2C19 P33261 1/20 0.67
PTGS2 P35354 1/20 0.67
SLC6A3 Q01959 1/20 0.67
HIF1A Q16665 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
MAOB P27338 9/20 0.66
APP P05067 1/20 0.66
GAA P10253 1/20 0.64
MAPT P10636 1/20 0.64
MAOA P21397 1/20 0.64
RAB9A P51151 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11840257 0.92 MAOB (0.62) MEN1ALDH1A1RECQLKMT2ALMNA
SCHEMBL6927496 0.91 MAOB (0.66) MEN1ALDH1A1RECQLKMT2ALMNA
4-Benzyloxyaniline SCHEMBL5571271 0.91 MAOB (0.83) MEN1ALDH1A1RECQLKMT2ALMNA
SCHEMBL1465278 0.89 KMT2A (0.70) MEN1ALDH1A1RECQLKMT2ALMNA
SCHEMBL27854180 0.89 MEN1 (0.57) MEN1ALDH1A1RECQLKMT2ALMNA
SCHEMBL27550091 0.89 MAOB (0.80) MAOBAPPRAB9ANR4A2
SCHEMBL339813 0.89 LMNA (0.82) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL27367676 0.89 LMNA (0.82) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL21993643 0.88 GSTP1 (0.63) MEN1ALDH1A1RECQLKMT2ALMNA
SCHEMBL11852684 0.88 MAOB (0.62) MEN1ALDH1A1RECQLKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117362236-B Synthesis method of flumazenil 江苏远恒药业有限公司 2024-05-03 CN claimed
CN-117362236-A Synthesis method of flumazenil 江苏远恒药业有限公司 2024-01-09 CN claimed
US-20090023075-A1 Nonaqueous electrolyte including Diphenyl ether and lithium secondary battery using thereof PANAX ETEC CO., LTD (KR) 2009-01-22 US claimed
EP-1979978-A1 NONAQUEOUS ELECTROLYTE INCLUDING DIPHENYL ETHER AND LITHIUM SECONDARY BATTERY USING THEREOF Cheil Industries Inc. (KR) 2008-10-15 EP claimed
WO-2007081151-A1 NONAQUEOUS ELECTROLYTE INCLUDING DIPHENYL ETHER AND LITHIUM SECONDARY BATTERY USING THEREOF CHEIL INDUSTRIES INC. (KR) 2007-07-19 WO claimed
CN-117362236-B Synthesis method of flumazenil 江苏远恒药业有限公司 2024-05-03 CN disclosed
CN-117362236-B Synthesis method of flumazenil 江苏远恒药业有限公司 2024-05-03 CN disclosed
CN-117362236-A Synthesis method of flumazenil 江苏远恒药业有限公司 2024-01-09 CN disclosed
CN-117362236-A Synthesis method of flumazenil 江苏远恒药业有限公司 2024-01-09 CN disclosed
CN-115806525-B Method for synthesizing alpha-triarylamine 深圳湾实验室 2023-05-23 CN disclosed
WO-2019111980-A1 CYCLOALKYLACETIC ACID-TYPE DIAMIDE DERIVATIVE 第一三共株式会社 2019-06-13 WO disclosed
US-20170342324-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MERCK PATENT GMBH (DE) 2017-11-30 US disclosed
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-14 US disclosed
CN-1649820-A Compounds that modulate PPAR activity and methods for preparing the same WARNER LAMBERT CO (US) 2005-08-03 CN disclosed
EP-1175408-A1 PYRIMIDINONE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2002-01-30 EP disclosed
WO-2000066567-A1 PYRIMIDINONE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-11-09 WO disclosed
CN-87105707-A Desinsection and the alkane and the alkoxy derivatives alkane that kill mite 1988-03-09 CN disclosed
EP-0009787-B2 PROCESS FOR THE MONOHALOGENATION OF ALKYLBENZENES IN ALPHA POSITION BAYER AG (DE) 1986-07-09 EP disclosed
EP-0009787-B1 PROCESS FOR THE MONOHALOGENATION OF ALKYLBENZENES IN ALPHA POSITION BAYER AG (DE) 1982-01-13 EP disclosed
EP-0009787-A2 Process for the monohalogenation of alkylbenzenes in alpha position BAYER AG (DE) 1980-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex AP1M1, OR10J3, AP2M1 MEN1 609/4885ALDH1A1 4017/4885RECQL 1984/4885
US-20170342324-A1 BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA MTX1, S100A11, MCRS1 MEN1 7/4885ALDH1A1 3730/4885RECQL 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.